Article
![Eruptive keratoacanthomas on the anterior and lateral distal leg, respectively, in a patient with melanoma who was treated with nivolumab. Eruptive keratoacanthomas on the anterior and lateral distal leg, respectively, in a patient with melanoma who was treated with nivolumab.](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/CT111005013_e_300x300.jpg)
Eruptive Keratoacanthomas After Nivolumab Treatment of Stage III Melanoma
- Author:
- Danielle Y. Sullivan, BS
- Greg K. Sakamoto, MD
Eruptive keratoacanthomas (KAs) are a rare buttransient adverse effect of programmed cell death protein 1 (PD-1) inhibitor therapy.